How we can encourage people to wear masks — for others’ sake

Governors, mayors, and public health officials are sounding the alarm about rising levels of Covid-19 across every part of the country. The disease is surging, the death toll is soaring, and it’s clear that some states need more restrictive measures to control the spread.

What continues to frustrate so many leaders is that nine months into this pandemic, science and data have painted a clear path for how to beat the virus and reduce transmission. But the disappointing and deadly truth is that in many cases, it’s difficult to get Americans to follow the rules.

Boosted by a president who celebrates breaking rules and deliberately defies science and time-tested norms of civility, millions of Americans have been flagrantly flouting simple requests to wear masks in public, to refrain from congregating in large groups, or to limit their unnecessary travel. With the rule-makers themselves publicly disregarding the recommendations of experts and scientists of their own administration, rule-breaking Americans have quickly followed.

As it happens, the US loves rule breakers; the ethos of breaking with tradition is in our country’s DNA. New Hampshire’s state motto is “Live Free or Die,” Western states like Arizona famously celebrate rugged individualism, the country’s founders are revered as rebels who defied a demanding government, and even a reality TV star could be elected president.

But in a pandemic, what public health officials are pleading for is a little more conformity. Flattening the curve requires Americans to all take fairly uniform actions — wearing masks, not gathering — for the betterment of the whole of society. It isn’t a time to bristle at being “told what to do.” President-elect Joe Biden has already signaled that he intends, unlike President Trump, to follow the science and issue a national 100-day mask-wearing campaign. While we wait for the months-long rollout of a vaccine to hundreds of millions of Americans, people must fall in line with this and other public health recommendations if there’s to be any hope of beating the virus. But will they?

While it may seem unlikely that Biden and public health officials can really encourage many more Americans to follow rules, there are ways to bring Americans together to support conformity. This, in turn, could help get Americans through the last several months of the pandemic with tens of thousands of fewer lives lost.

It’s important to think carefully about the message, because there’s more than one type of conformity. The type we think about most often — self-focused conformity — describes actions taken to fit in with a group. (These can be conspicuous inactions, too, such as some Trump supporters refusing to wear masks.)

But my research with collaborator Matthew Wice, assistant professor of psychology at SUNY New Paltz, looks at others-focused conformity, what we call “benevolent conformity,” and shows how following norms or rules can benefit others.

In one study, we asked more than 300 participants to think back to a time when they saw someone conform to their group. Some participants were asked to think about an instance when someone conformed because they wanted others to like them. Others were asked to think about a time when someone conformed for others’ sake. We then asked all of our participants to report what they thought about this person whose public behavior differed from their privately held beliefs. Did this person have a strong moral character? Were they competent people? Were they kind and friendly?

While participants in our research scoffed at conformity when it was perceived as selfish, they respected and appreciated benevolent conformity, seeing it as courageous and praiseworthy. Our experiments showed that Americans found people who conform to protect others’ feelings or to maintain group harmony to be warmer, more competent, and more authentic.

This is a key lesson for Biden and for governors who seek to enforce conformity to help protect people from a deadly virus. They should emphasize that sometimes conformity takes courage. This point should be made loud and clear: In the battle against Covid-19, the courageous and commendable thing to do is to put other people first.

So when presented with the idea that following Covid-19 safety measures is “weak” or “un-American,” public health experts should flip this argument on its head: emphasize the benefits of people’s helpful actions. Wherever possible, leaders must employ the benevolent conformity Americans seem to gravitate toward and respect.

Emphasizing a strong sense of shared identity can remind Americans that the real reason for adhering to safety measures is not just to fit in, but also to protect the group to which they belong. When adhering to simple safety measures can save tens of thousands of American lives, wearing a mask is not an act of blind obedience, it is an act of patriotism. As vaccines begin to be deployed (with vaccine hesitancy still high) and the pandemic reaching new heights, this kind of messaging will be increasingly urgent to get us back on track.

Our research makes one thing clear: Americans love rule breakers, but they also hold a special place in their heart for benevolent, other-focused rule followers. If 2020 has shown us anything, it’s that sometimes, we need to conform for others’ sake.

Click Here:

Shai Davidai is assistant professor in the management division of Columbia Business School with expertise in the psychology of judgment and decision-making, economic inequality and social mobility, social comparisons, and zero-sum thinking. A social psychologist, his research examines people’s everyday judgments of themselves, other people, and society as a whole.

The 4 major unknowns of how vaccines will affect the Covid-19 pandemic

Two highly effective Covid-19 vaccines are now being administered across the United States, and more are in the pipeline. Almost 2 million people have already received the first of two doses of these vaccines, and officials are aiming to immunize one-third of the US population by the end of March 2021.

It’s a stunning accomplishment for a disease that was barely known to the world a year ago, and it means that an end to the crisis is in sight. Yet the US remains in the worst throes of the pandemic to date, with hospitalizations and deaths continuing to break records.

Vaccines are critical in drawing down the pandemic as we know it, but it won’t be a simple return to the world before Covid-19. It will likely be a process that lasts several months, and precautions like social distancing and wearing masks will still be needed until there is widespread immunity to the virus.

“It’s a bit of a glide path in my mind toward a new normal, and a new normal that will continue to get better and better,” said Ashish Jha, dean of the School of Public Health at Brown University. “Ultimately, the mental model that I’m going for is ‘When are people going about their day and not thinking about Covid?’”

Exactly when and how this will happen hinges on several key variables relating to vaccines that scientists and health officials are still trying to sort out.

The vaccines being administered right now — the Moderna vaccine and the Pfizer/BioNTech vaccine — have only received emergency use authorizations, not full approval, from the Food and Drug Administration. Regulators have determined that the benefits of the vaccine outweigh the risks for most adults at high risk of exposure, but there are still some unanswered questions, such as how long protection lasts and how well these vaccines block transmission of the virus between people.

And beyond the vaccines themselves, how quickly and how readily people accept them can change the course of the pandemic.

How well a Covid-19 vaccine contains the pandemic depends on the answers to several key questions

The clinical trials for Covid-19 vaccines are still ongoing, and more clarity will emerge in the coming months. But for now, these remain some of the most important unknowns.

How well do vaccines prevent the spread of SARS-CoV-2?

Both the Moderna vaccine and the Pfizer/BioNTech vaccine reported efficacies of roughly 95 percent against Covid-19 disease, meaning they protected the vast majority of recipients from getting sick enough to have disease symptoms, like loss of smell, fever, and cough.

However, Covid-19 is caused by a virus, SARS-CoV-2, that some people can carry and transmit without having any symptoms at all — whether or not they eventually end up feeling ill.

Finding the people who are carrying the virus (and preventing them from infecting others) is therefore critical to control the spread of the virus, but has proven to be a persistent obstacle during the pandemic. Currently, the main way to identify the infected is by proactively testing for the virus and, ideally, tracing who else they encountered. It’s a tedious, time-consuming process.

This is also true in vaccine clinical trials. Phase 3 trials mainly look at how well vaccines prevent disease in the real world, something that’s readily apparent when comparing the number of disease events in the vaccine group to the placebo group. It only takes 150 events or so to yield results on how well the vaccine prevents disease.

But to gauge efficacy against preventing infections, including low-grade infections that don’t generate symptoms, researchers will have to test the tens of thousands of participants in their phase 3 trial. It’s likely that a Covid-19 vaccine would reduce transmission, but it’s not clear yet by how much.

“What we know is that we’ve been seeing studies focusing specifically on efficacy with regards to severity of disease, meaning ameliorating the severity of the disease itself, but there’s still no studies that really are going to help us understand how we can certainly interrupt transmission,” said Maria Elena Bottazzi, a co-director of the Texas Children’s Hospital Center for Vaccine Development.

The companies conducting trials do plan to test their participants to see if there were any hidden infections, but it may be a while before they report their results.

That said, Moderna presented some early data showing that its vaccine does begin to reduce infections between its doses, which are spaced 28 days apart.

“There were approximately 2/3 fewer swabs that were positive in the vaccine group as compared to the placebo group at the pre-dose 2 timepoint, suggesting that some asymptomatic infections start to be prevented after the first dose,” according to Moderna’s report to the FDA. However, these results are preliminary and will require follow-up testing to see if this effect lasts longer than a few weeks.

The more that a vaccine can reduce the virus’s transmission, the more quickly a population can move toward herd immunity, the point where the virus can no longer spread easily between people. Scientists estimate that herd immunity threshold is when roughly between 60 percent and 90 percent of a population is immune to this virus, whether through a vaccine or from natural exposure. (A recent study in the New England Journal of Medicine showed that health workers in the United Kingdom exposed to SARS-CoV-2 produced protective antibodies against the virus and were protected against reinfection for at least six months.)

But vaccines might not protect every single person who gets a shot from getting infected, just like they don’t provide a 100 percent guarantee against getting sick. That means even the vaccinated will still have to wear face masks and keep their distance from others to prevent virus transmission until immunity is widespread.

How long do vaccines protect against Covid-19?

The Moderna and Pfizer/BioNTech trials have shown that their vaccines start to provide protection against Covid-19 illness quickly — and that protection starts building up right after the first dose.

Whether that protection fades after a few months or a few years is unclear. And researchers can only find out by waiting and observing. That means monitoring the thousands of participants of clinical trials, as well as recipients of the vaccines in the general population, for years. Pfizer and BioNTech, as well as Moderna, have committed to actively monitoring the participants in their clinical trials for at least two years. They are also keeping an eye on people who are receiving their vaccines.

But hints on the durability of vaccine protection could arrive sooner. Looking at vaccine recipients six months or one year after they receive their injections, researchers should be able to see how many were infected with SARS-CoV-2 — and when — to get an early estimate of how quickly protection weakens.

“That would give us potentially some information for what future years will look like,” said Meagan Fitzpatrick, an assistant professor at the center for vaccine development and global health at the University of Maryland School of Medicine. “You will definitely get some signal, but you don’t know really for sure in a way that’s backed up by data until that amount of time passes from when the first people got their first doses.”

Longer protection would buy time for the health sector as vaccines roll out since they wouldn’t have to worry about reinfections or revaccinating people. Evidence from past coronavirus outbreaks like SARS and MERS showed that among survivors, protection for those diseases lasted for several years. But SARS-CoV-2 is a new virus, and much remains uncertain.

There’s also a chance that SARS-CoV-2 could mutate in a way that would escape the protection offered by a vaccine. However, scientists say that’s unlikely in the near term because Covid-19 vaccines target several different parts of the virus and the odds of simultaneous mutations in all of those regions are low.

But more study is needed to yield more definite answers, and the best way to reduce the likelihood of major mutations in SARS-CoV-2 is to limit its spread.

How quickly can we get the vaccine to everyone?

The United States is now in the midst of its largest vaccination campaign in history, an endeavor that’s anywhere from three to four times as big as vaccinating against seasonal flu, according to Moncef Slaoui, the scientific lead for the Department of Health and Human Services’ Operation Warp Speed vaccine program.

It’s a delicate and critical process. “How soon can we really start driving our Covid numbers low really definitely depends on rollout,” Fitzpatrick said. “A vaccine is only as good as the doses that actually get into people.”

However, the debut of Covid-19 vaccines has already hit several bumps. Some states have reported that their initial allotments of the Pfizer/BioNTech vaccine were cut, while the manufacturer reported that many doses have gone unclaimed.

Part of the challenge is technical constraints of the vaccines themselves. Both the Moderna and the Pfizer/BioNTech vaccines require maintaining cold temperatures from factories to transportation to clinics. The Pfizer/BioNTech vaccine in particular demands ultra-cold storage at temperatures of minus 70 degrees Celsius (minus 94 degrees Fahrenheit).

Another complicating factor is simply sorting out who should get the vaccines and when. Enough doses are not immediately available for everyone, so health officials have to make delicate decisions about who to prioritize.

The vaccines available so far have to be administered as two doses spaced several weeks apart, so everyone will have to come back for a second shot. Doses have to be set aside for follow-ups and if people don’t get their second dose, they may have protection that’s less robust or less durable than expected. In a large enough population, that could erode the power of a vaccine to contain the virus.

At the same time, health officials will have to overcome vaccine hesitancy. Getting a high uptake of vaccines is critical in drawing down pandemic restrictions. And the more holdouts there are, the longer it will take. The good news is that reluctance to getting a vaccine seems to have diminished in the United States. A recent poll by the Kaiser Family Foundation found that 71 percent of Americans said they would likely get a Covid-19 vaccine, up from 63 percent in September.

A vaccine is not just about protecting individuals, but protecting a population as a whole. With enough people immunized, even people who haven’t received the vaccine — including those who can’t get vaccinated for health reasons — will experience a much lower risk of infection.

“If you really, really, really want to interrupt and really get rid of this pandemic, you really need high levels of [vaccine] coverage and very high levels of efficacy,” Bottazzi said.

And over the coming months, more Covid-19 vaccines will likely gain approval. That will help ease some of the supply constraints, but will add to the complexity of administering them. Each vaccine has its own storage requirements, dosing schedule, and may be best suited for different demographics.

Taken together, there’s a lot that can go wrong with distributing vaccines. But getting these steps right would mean a much faster route out of the Covid-19 crisis.

How well will the US control the spread of the virus?

In addition to vaccinating millions of people, controlling the spread of SARS-CoV-2 is critical. Efforts to contain the virus will allow the vaccine to have a much greater impact. Vaccines could be targeted to hot spots, for instance, rather than having to push back against a national onslaught.

As mentioned earlier, curtailing the virus’s transmission also reduces the likelihood of a mutation that could render a vaccine less effective. (But if virus variants discovered in the UK that appear more transmissive spread widely in the US, that could complicate efforts of curbing spread, even if the vaccine is just as effective against these variants.)

If all goes fairly well with the logistics of vaccine distribution, it will take weeks to months for it to actually start reducing hospitalizations and fatalities from Covid-19.

A vaccine is meant to prevent illness, so it will do little for people who are already ill with Covid-19. And the SARS-CoV-2 virus can incubate in a person for up to two weeks before the individual starts to show symptoms, and it can take longer after that for them to seek treatment.

As such, there will be a lag in seeing the impacts of a vaccine across the population. But slowing the spread of the virus would make vaccines a more powerful tool to end the pandemic, and results would start to manifest much sooner. Vaccination is also going to be working in tandem with immunity people have built up from surviving infection. Almost 20 million people in the US have been infected to date. “Around 30 percent population immunity, things start slowing a little bit, especially in the places that have been hit hard,” Jha said.

Conversely, if Covid-19 continues to rage out of control, it will be much harder for a vaccine to make a difference in morbidity and mortality, and it will take even longer to see results.

We still need testing, masking, distancing, and treatments

While scientists and health experts have been elated at the speed at which Covid-19 vaccines have been developed, they’ve also been adamant that vaccines on their own are not enough to control the Covid-19 pandemic.

The existing measures for slowing Covid-19 remain just as important as they’ve ever been, if not more so, given that hospitalizations and daily deaths are continuing to mount. Tactics like wearing face masks, rigorous hand-washing, and avoiding large gatherings and close contact with others will still be needed in the coming months, even among people who have been immunized.

Treatments for Covid-19 are also critical since they are the most immediate way to reduce fatalities. Approaches like monoclonal antibodies will be needed to help people survive the illness.

Widespread testing for Covid-19 will also continue to be crucial to identify potential spreaders and to allow people in key jobs to continue working.

It’s a sliding scale between these variables. For example, better testing and tracing could allow people more freedom even if they are not immune. Or effective treatments can drastically reduce fatality rates, reducing the burden of the disease.

However, pressure on all fronts — vaccines, treatment, testing, social distancing — is what will end the crisis the soonest. “The vaccine works at a population level a lot faster if we’re introducing it into a context into which we are throwing all of our other methods to interrupt the virus,” Fitzpatrick said.

While millions of people are growing weary of all the drastic restrictions imposed by the pandemic and the efforts to contain it, keeping them up in the coming months will help ensure that the US finds the quickest and least painful way out of routines bound by Covid-19.

Click Here:

The worst idea of 2020

It’s year-end-list season. Usually, the Vox science team has some fun and compiles a year-end list of bad ideas in health and science that ought to die with the end of the year. In the past, we’ve targeted homeopathic medicine, declared it was time to end the relevance of the fatally flawed Stanford Prison Experiment, and dispelled myths about climate change. This year, though, we have only one target for intellectual demolition.

With the end of 2020, let’s leave behind the idea of using herd immunity acquired through natural infections as a means of combating the Covid-19 pandemic. That’s a lot of words to describe a simple, terrible idea: that we could end the pandemic sooner if more people — particularly young, less at-risk people — get infected with the coronavirus and develop immunity as a result.

As a response to a pandemic, the idea is unprecedented. “Never in the history of public health has herd immunity been used as a strategy for responding to an outbreak, let alone a pandemic,” World Health Organization Director-General Tedros Adhanom Ghebreyesus said in October. “It is scientifically and ethically problematic.”

And yet it held sway — at the White House, in particular.

Former White House adviser Scott Atlas (who is a neuroradiologist, not an epidemiologist) was particularly vocal about pursuing more infections. “When younger, healthier people get infected, that’s a good thing,” Atlas said in a July interview with the San Diego news station KUSI-TV. “The goal is not to eliminate all cases. That’s not rational, it’s not necessary if we just protect the people who are going to have serious complications.”

Let’s be clear: It’s not a “good thing” when young people get sick. For one, some of these young people may die, more may get severely ill, and a not-yet-understood proportion of them could suffer long-term consequences. The more people infected, the more chances for rare, horrible things to happen, like a 4-month-old developing brain swelling after testing positive for Covid-19. For that reason, among others, attempting to keep infections to only young or lower-risk people is a foolhardy game to play.

Why building up herd immunity through natural infections is a bad idea

There’s an almost-understandable case for why some people would push for a herd immunity strategy. We are isolated from those we care about, businesses are hurting, education has suffered, and so has our mental health. What if we could just get back to some parts of normal life and contain the risks to those who are least likely to get hurt?

This thinking has proved reckless. Sweden, a country that pursued a more permissive strategy when it came to social distancing, has a much higher death rate than fellow Scandinavian countries.

And look at what happened in Manaus, Brazil: The city of around 2 million people experienced one of the most severe, unchecked Covid-19 outbreaks in the world. Researchers now estimate that between 44 and 66 percent of the city’s population was infected with the virus, which means it’s possible herd immunity has been achieved there (another estimate pegged the infection rate at 76 percent). But during its epidemic period, there were four times as many deaths as normal in Manaus for that point in the year.

More typically, the term “herd immunity” is referred to in the context of vaccination campaigns against contagious viruses such as measles. The concept helps public health officials think through the math of how many people in a population need to be vaccinated to prevent outbreaks. It’s not meant to be applied to control a pandemic through natural infection. Here are five reasons why:

  1. Even if we could limit exposure to the people least likely to die of Covid-19, this group still can suffer immense consequences from the infection — such as hospitalization, long-term symptoms, organ damage, missed work, high medical bills, and yes, death.
  2. Herd immunity is a very high bar to reach from natural infections. There’s no single, perfect estimate of what percentage of the US population has already been infected by the virus. But by all accounts, it’s nowhere near the figure needed for herd immunity to kick in. The CDC now estimates that there have been 91 million SARS-CoV-2 infections in the US — around 27 percent of the population (though this may be an overestimate). It would take around 60 percent of the population to achieve herd immunity. That’s a rough guess; it could be higher. So we’re about halfway there. Who wants to double the destruction already caused by this virus? In the US, more than 330,000 people have died. (Plus, herd immunity doesn’t work on a nationwide basis but a community-by-community basis. In other words, some communities are still much more vulnerable than others.)
  3. Scientists don’t know how long naturally acquired immunity to the virus lasts, or how common reinfections might be. If immunity wanes and the reinfection rate is high, it will be all the more difficult to build up herd immunity.
  4. By letting the pandemic rage, we risk overshooting the herd immunity threshold. Once you hit the herd immunity threshold, it doesn’t mean the pandemic is over. “All it means is that, on average, each infection causes less than one ongoing infection,” Harvard epidemiologist Bill Hanage told me. “That’s of limited use if you’ve already got a million people infected.” If each infection causes an average of 0.8 new infections, the epidemic will slow. But 0.8 isn’t zero. If a million people are infected at the time herd immunity is reached, per Hanage’s example, those already-infected people may infect 800,000 more.
  5. A herd immunity strategy is likely to harm some groups more than others. There are multiple reasons someone could experience a severe case of Covid-19. It’s not just age — conditions such as diabetes and hypertension also exacerbate risk. So do societal factors including poverty, working conditions, and incarceration.

In the US, severe Covid-19 deaths have disproportionately impacted minorities and less advantaged populations. Encouraging herd immunity through coronavirus infection risks further isolating these already marginalized communities from society, since they may not feel safe in a more relaxed environment. Or, even worse, we risk sacrificing their health in the name of reaching a level of population immunity sufficient to control the virus.

Soon, herd immunity will be a good thing — because of vaccines

Thankfully, we now have a means of building up herd immunity without the risks conferred by infections: vaccines. Unlike the immunity conferred by an actual viral infection, immunity obtained via vaccine doesn’t come with the cost of sickness and death. Vaccines are safe. And while they won’t turn the pandemic around overnight, they will help end it.

We still have to do some difficult waiting. Vaccine rollouts will be slow. Throughout 2020, “herd immunity” was used as a stand-in for “let the pandemic spread.” There was also persistent and erroneous wishful thinking by some who said herd immunity had already been reached, or could be reached sooner than scientists say, or without incurring horrible losses. Yes, the economic restrictions of the pandemic were, and still are, painful. But it’s also true the government could have done more to help.

Soon, herd immunity will become a good-news phrase as we build toward it collectively — and safely — through vaccines. As the vaccines get distributed, herd immunity will develop in a controlled, ethical manner. The pandemic will wane.

And as it does, let’s not forget: The calls to build up herd immunity through infections were a terrible idea. Let’s not repeat them in the future.

Correction: An earlier version of this article misstated the Covid-19 death rate in Sweden compared to other European countries.

Click Here:

In 2020, scientists documented hundreds of new species. Here are a few.

It’s the year 2020, and scientists are still discovering new species of life on Earth. No one knows exactly how many types of life are yet undescribed in the scientific literature; estimates range from around 86 percent to as high as 99.99 percent. And even though we’re living through an age of great biodiversity loss, the scope and breadth of life on planet Earth is still revealing itself to scientists around the world.

This year, researchers at the California Academy of Sciences have described 213 new species in scientific journals: “101 ants, 22 crickets, 15 fishes, 11 geckos, 11 sea slugs, 11 flowering plants, eight beetles, eight fossil echinoderms, seven spiders, five snakes, two skinks, two aphids, two eels, one moss, one frog, one fossil amphibian, one seahorse, one fossil scallop, one sea biscuit [a.k.a. sand dollar], one fossil crinoid (or sea lily), and one coral,” the academy lists in a press release.

These species weren’t necessarily first spotted this year. Instead, they were officially described in the scientific literature as unique species, some after decades of research.

Terry Gosliner, a curator of invertebrate zoology at the California Academy of Sciences, added one species of sea slug he first saw on a dive in the Philippines 23 years ago. As a sea slug expert, he knows immediately when he’s spotted one he hasn’t seen before. “It’s like if you walk into a room, and you know, almost immediately, if there’s a person in there who you haven’t met before,” he says.

But on that first encounter decades ago, Gosliner didn’t collect a specimen that would allow for DNA analysis, which is crucial for understanding if a presumed new species is actually new to science. Plus, this particular sea slug was nocturnal. “You just happen to have a chance encounter with it on a night dive,” he says. He found a second specimen in 2010. By then, “it was like encountering an old friend that you hadn’t seen forever,” he says.

It’s taken even more time to determine that this creature — now named Hoplodoris rosansis a truly new entry in the scientific books of life. “The easiest part is finding them,” Gosliner says of discovering new species. The hard part is the scientific work that comes next.

After finding a species, “it’s a very lengthy process after that,” he says to describe a new species. Scientists need to study the DNA, the internal anatomy and external anatomy, “so that you can make comparisons about how that species differs from all the other species that are known.” Then those discoveries have to be written up and submitted to a peer-reviewed journal.

Gosliner and his colleagues also got to name the new species. They call it Hoplodoris rosans for a few reasons. Hoplodoris is the genus of the sea slug. But its species name, rosans, is named after the rose. They chose that because, for one, there are reddish-pink spots on the underside of the body. And two: “It has in its reproductive system this very large spine that holds mates when mating that was shaped like a rose thorn,” Gosliner says.

Along with Hoplodoris rosans, researchers at the California Academy of Sciences have described this year:

A pygmy seahorse about the size of a grape, called Hippocampus nalu.

A gecko residing in the city of Guwahati, India, called Cyrtodactylus urbanus.

The first species of pipefish known to live among red algae, called Stigmatopora harastii.

A newly described flowering plant in Brazil in the Microlicia genus, Microlicia capitata.

And a new sea biscuit (sand dollar) in the Philippines, Clypeaster brigitteae.

Why scientists need to keep documenting life on Earth. And how you can, too.

It’s been a tough year full of sickness and death with the Covid-19 pandemic. It’s hopeful knowing how much there is yet to be discovered about our world. And it’s important work, too.

Between 2010 and 2020, 467 species have been declared extinct (though they might have actually gone extinct in decades prior), according to the global authority on species conservation status, the International Union for Conservation of Nature, or IUCN. Others have been brought to the brink, and still more are seeing serious declines in their population numbers.

In all, the UN’s Intergovernmental Science-Policy Platform on Biodiversity and Ecosystem Services estimates as many as 1 million species are now at risk of extinction if we don’t act to save them; that number includes 40 percent of all amphibian species, 33 percent of corals, and around 10 percent of insects.

A species can be discovered nearly anywhere: In 2012, a new species of ant was discovered in New York City, of all places. If you’re interested in species sleuthing, Gosliner recommends using the iNaturalist app to document critters and plants you see out in the world.

There, a community of citizen scientists can help determine if what you’ve scouted is truly new. And you don’t need to find something new, per se, to contribute to science. “Just yesterday,” he told me on December 18, “on iNaturalist there was a species of nudibranch [sea slug] that was found in the tide pools just south of San Francisco, that nobody had seen for many, many years. And so that was a really exciting thing to have documented.”

To protect more species, scientists need to know they exist in the first place.

“Describing new species is really documenting biodiversity on the planet,” Gosliner says. “There’s so many areas that we may lose species before we even know that they existed. If you never knew it existed, [and] then it disappeared — that’s kind of a tragedy from my standpoint. There’s the element of the excitement of discovering something new. But also, there’s the urgency that we really need this information to be able to protect biodiversity on the planet.”

Click Here:

History for Ardscoil Rís as they take a first colleges title back to Limerick

Updated Thu 8:10 PM

Ardscoil Rís 1-17
St Kieran’s College 0-15

Robert Cribbin reports from Croke Park

ARDSCOIL RÍS OF Limerick captured their first ever All-Ireland senior hurling colleges title after claiming a five-point victory over Kilkenny aristocrats St Kieran’s College in Croke Park this afternoon.

Ardscoil Rís were appearing in their fourth ever final and after losing out in all three previous deciders to St Kieran’s in 2010, 2011 and 2016, Niall Moran’s side finally reversed the trend.

Kieran’s themselves were in a seventh consecutive showpiece and they were hoping to make it five wins in six, and despite Harry Shine giving them an opening minute lead, they were chasing shadows for the majority of the contest as the Limerick school were fully warranted winners.

Advertisement

Despite Niall O’Farrell squandering a 19th minute penalty for the Munster finalists, the youngster who was a late addition to the team caused huge problems for Kieran’s as he finished with seven points in total.

It was nip and tuck up until that point with Kieran’s leading 0-5 to 0-4 after Shine and Joe Fitzpatrick impressed early on but the final 10 minutes of the half belonged to Ardscoil Rís as they hit six points on the trot to go into the break with a commanding advantage.

Click Here:

Source: Tom Maher/INPHO

As they always tend to do, Kieran’s battled back and when they got within two points of their opponents with the wind at their back they appeared to be in prime position to catch the Limerick side in the final stretch.

Unlike previous years, though, it was Niall Moran’s Ardscoil Rís team who finished the better and when David Kennedy shot past Alan Dunphy in the 55th minute for the game’s only goal, celebrations could begin in earnest as they powered to a 1-17 to 0-15 success.

Scorers for Ardscoil Ris – Niall O’Farrell (0-7, 0-4f, 0-1 65), David Kennedy (1-3), Shane O’Brien (0-4), Rian O’Byrne, Jack Golden, Dylan Lynch (0-1 each).

Scorers for St Kieran’s College – Harry Shine (0-4, 0-2f), Joe Fitzpatrick (0-4, 0-1f), Ben Whitty (0-3, 0-1 65), James Carroll, Donagh Murphy, Padraig Naddy, Paddy Langton (0-1each).

SEE SPORT
DIFFERENTLY

Get closer to the stories that matter with exclusive analysis, insight and debate in The42 Membership.

Become a Member

Ardscoil Ris – Seimi Gully; Evan O’Leary, John Fitzgerald, Colm Flynn; Michael Gavin, Cian Scully, Vince Harrington; JJ Carey, Rian O’Byrne; Shane O’Brien, Niall O’Farrell, Jack Golden; Brian O’Keeffe, Oisin O’Farrell, David Kennedy. Subs: Dylan Lynch for Flynn 48 mins, Diarmuid Stritch for O’Byrne 58 mins, Sean McMahon for O’ Keeffe 59 mins.

St Kieran’s College- Alan Dunphy; Jack Butler, Adam O’Connor, Paddy Langton; Padraig Lennon, Joe Fitzpatrick, Conor Cody; James Carroll, Killian Doyle, Ted Dunne, Harry Shine, Ben Whitty, Donagh Murphy, Luke Connellan, Padraig Naddy. Subs: Anthony Ireland Wall for Naddy 41 mins, Alex Sheridan for Murphy 51 mins, Nick Doheny for Dunne 56 mins.

Referee – Liam Gordon (Galway)

The42 is on Instagram! Tap the button below on your phone to follow us!

Big electric trucks and buses are coming. Here’s how to speed up the transition.

There’s a growing consensus in the climate change community that the key to transitioning the US economy from fossil fuels is to electrify everything — shift the electricity grid over to carbon-free power and shift other big polluting sectors like transportation and heating over to electricity.

When it comes to transportation, electrification is going to be tricky. Not long ago, the consensus was that the cost and power limitations of batteries would make it difficult to fully electrify anything larger than passenger vehicles.

But batteries have been progressing in leaps and bounds. Full electrification is still beyond the reach of huge vehicles, the long-distance airliners and container ships, but recently it has become a possibility for a large and significant category of vehicles in the middle: medium- and heavy-duty trucks and buses.

According to the Environmental Protection Agency, just 6 percent of the registered vehicles on US roads in 2018 were medium- and heavy-duty, but they were responsible for 23 percent of transportation-sector greenhouse gas emissions (about 7 percent of total US emissions).

Since they mostly run on diesel engines, they also produce enormous amounts of air and noise pollution, which fall disproportionately on low-income and communities of color that may live closer to highways and are more likely to use buses. Long-haul trucks alone, while responsible for less than 6 percent of vehicle miles traveled on US highways, produce about 40 percent of its particulate pollution and 55 percent of its nitrogen oxides.

The global toll is immense: 180,000 deaths a year from diesel pollution.

That’s where medium- and heavy-duty electric trucks (MHDETs) come in. They are quiet, emit zero tailpipe pollution, and draw power from an increasingly clean electricity grid. An impossible dream a decade ago, they are now the subject of fierce competition from big automakers like Daimler, Volvo, VW, and Tesla, with multiple models slated to hit the road in coming years.

As countries across the world start cracking down on carbon emissions — and cities ramp up their fight against diesel pollution — there’s going to be an enormous market for clean alternatives. According to the Department of Transportation, there are over 14 million large trucks and buses on US roads. Wood Mackenzie expects the number of electric trucks on US roads to rise from 2,000 in 2019 to more than 54,000 by 2025, around 27 times growth. The research firm IDTechEx expects the MHDET market to reach $47 billion by 2030.

Demand is partly being driven by big fleet owners like Amazon, Walmart, Ikea, Anheuser-Busch, and Pepsi, which are transitioning to MHDETs. (Amazon recently ordered 100,000 electric delivery vans.)

Policymakers are helping, too. In July, governors of 15 states signed a memorandum agreeing to set up a MHDET task force, develop an action plan, and jointly “strive to make sales of all new medium- and heavy-duty vehicles in our jurisdictions zero emission vehicles by no later than 2050,” and in the interim, “strive to make at least 30 percent of all new medium- and heavy-duty vehicle sales in our jurisdictions zero emission vehicles by no later than 2030.” New York City, Los Angeles, Houston, and other cities are already exploring electric buses.

And don’t forget Jeff Bezos. One of his big climate gifts was $100 million over five years to the World Resources Institute, which will use it in part on a program to electrify school buses. Before him was the Hewlett Foundation’s 2020 Zero Emission Road Freight Strategy 2020-2025.

MHDETs are gaining momentum and there is every reason to believe that they will come to dominate the market. But societies do not have to simply sit back, watch markets, cross their fingers, and hope for the best. They can accelerate the spread of MHDETs — and their associated health and climate benefits — by targeting the many barriers that remain in a smart, proactive way.

To get a better sense of those barriers and opportunities, let’s look at two reports that were recently released on the subject, one from the Electrification Coalition (a collection of businesses and nonprofits) and one from the Environmental Defense Fund (EDF). Both focus on the challenges of electrifying MHDETs and how to overcome them.

The total cost of fleet electrification remains high

The purchasers of big buses and trucks are not typically buying single vehicles. They are almost all managers of fleets of vehicles. So the question of whether to electrify goes beyond whether the next truck might be cheaper electric. Electrifying a fleet is a big, complicated process that involves buying and installing new charging infrastructure and changing operational procedures, in the face of considerable uncertainty and risk.

EDF offers a framework that tries to pull all these costs and risks together into a single metric: the total cost of electrification (TCE). TCE goes beyond the conventional metric of total cost of ownership (TCO), meant to be inclusive of capital, operations, and infrastructure costs, to include less quantifiable social, operational, and even psychological costs.

So what are these barriers to MHDETs? The Electrification Coalition identifies nine:

1. Higher upfront vehicle costs and associated tariffs

Several surveys have found that the higher upfront costs associated with fleet electrification — not only the vehicles but the associated infrastructure — are the primary deterrent for fleet managers. And upfront costs are higher today, though that is changing. Bloomberg New Energy Finance expects medium-duty EVs to reach cost parity by 2025 and heavy-duty EVs by 2030.

Here’s a graph from the Hewlett Foundation showing when TCO parity will be reached by various kinds of electric trucks. Note that all classes of EV trucks will be cheaper on a TCO basis by 2030:

In addition, new heavy-duty trucks face a steep (12 percent) federal excise tax, which is even more on the higher-price EVs.

Click Here:

“The near-term higher upfront costs associated with MHDETs are likely to remain a substantial barrier to fleets for the next five to 10 years,” the Coalition writes.

2. Costly and complex charging infrastructure processes

Fleet managers are daunted by the complicated considerations involved in determining how much charging infrastructure is needed to support a fleet of MHDETs, finding a way to pay for it, and then fighting through the siting, permitting, and interconnecting hassles.

3. Early market and limited model availability versus limited fleet demand

Because there hasn’t been much regulatory pressure and MHDETs are relatively new and untested, fleet managers have been wary and demand has been low; because demand has been low, there are limited models and options available. (This should change soon as models roll out in coming years.)

4. Entrenched market advantages of diesel trucks

Diesel has been playing a big role in commercial transportation for a century; consequently, the vehicles, supply chains, and service networks are well-developed. MHDETs are newer and still trying to work all that stuff out.

5. Commercial and industrial electricity rate structures not aligned to charging needs

On average, electricity is a cheaper fuel than gas or diesel, but that cost advantage can be eroded or erased by bad rate design, with fixed rates or high peak charges.

6. Lack of verified data on total cost of ownership and performance specifications

Because there aren’t that many MHDETs on the road, and pre-production models don’t release their specs, it can be difficult for fleet managers to verify whether particular MHDETs can meet their fleet’s operational needs.

7. Limited availability of certified service centers and technicians

Again, because this is nascent technology, there aren’t many support services and trained technicians — that’s a major problem when it comes to these big vehicles because they tend to be used intensely and require continual support.

8. Concerns with grid resiliency

As more fleets electrify, there are greater concerns about the pressure put on electrical infrastructure that is in some cases already under stress, especially in congested areas. “Without proactive evaluation and investment to support these potential grid and generation upgrades,” the Coalition writes, “the transition to electrified freight could see significant delays and infrastructure impediments.”

9. Antiquated vehicle and facility ownership structures

Many fleet operators use leased facilities that may not have the infrastructure to handle electrification, and even if they can persuade the owners to allow upgrades, they have little incentive to take on all the costs for a property they don’t own. The cost of facility upgrades needs to be shared, perhaps with utilities as well.

As you can see, some of these problems involve “hard costs” like equipment and infrastructure, some involve “soft costs” like operational changes, and others are simply risks, which impose costs of their own. Fleet managers are not hyper-rational interest maximizers. They have limited knowledge, time, mental energy, and staff to devote to these questions. These frictions and uncertainties — about infrastructure, battery performance, maintenance costs, shifting public policies — can easily become overwhelming. The old ways of doing things, maintaining and ordering more diesel vehicles, have their own inertia.

Measures to accelerate MHDETs must target the full range of barriers.

Financing and policy tools can hasten the spread of electric trucks and buses

There are lots of financing, policy, and private-sector tools that can reduce the barriers to fleet electrification. Both reports get pretty deep in the weeds, so I will just briefly summarize. The Electrification Coalition offers the simplest way of dividing up the toolkit:

1. Policy

Local, state, and federal governments can all takes steps to boost MHDETs, including targets for vehicle sales, programs to fund and expand charging infrastructure, clean fuel standards (like California’s), and purchase incentives, among others.

2. Utilities

Utilities can set up programs that support private investment in vehicle charging infrastructure. They can more carefully and comprehensively assess the impact of EV growth on electricity demand, in order to plan and invest wisely. Perhaps most of all, they can reform electricity rates to be friendlier to electric fleets.

3. Supply chain

Participants in the MHDET supply chain can work to ease frictions as well. They can standardize charging connectors, invest in smart, networked EV charging management software, take proactive steps to guard against upstream supply disruptions (by diversifying materials), and set up a network of MHDET service centers and trained technicians.

4. Corporations

Corporations that want to clean up their operations can set deployment goals for MHDETs and run pilot programs for new vehicles and networks. They can combine fleet orders and make big purchase commitments to help drive economies of scale.

5. Collaboration

All the aforementioned parties will need to work together to share knowledge and best practices, technical and funding support, and outreach to the public and other stakeholders.

This barely scratches the surface, of course. (EDF has its own extensive list of tools.) But it gives a sense of the breadth of instruments and participants involved. All that’s required to drive MHDETs to market scale is the leadership to get this kind of cooperative action moving.

Unlike a carbon price, real industrial policy is going to be complicated and messy

For many years, climate policy wonks looked at the vast array of economic sectors and activities that must change in order to substantially reduce carbon emissions and concluded that the best and most efficient way forward was to change them all at once, with a single instrument: a price on carbon. Pulling on that one lever would move every part of the economy in concert. It is an elegant dream.

The fixation on carbon pricing lives on in many quarters, but for many climate hawks the elegant dream does not match how politics or people actually operate. What has worked in the past, and is likely to work in the future, is industrial policy: targeted, sector-specific efforts to accelerate some technologies and practices and phase others out. Industrial policy is at the heart of the new climate policy alignment on the left, evident in the Green New Deal, in the many policy platforms and proposals that spilled out of it, and in President-elect Joe Biden’s climate plan.

Industrial policy doesn’t look like an elegant dream. It looks like these reports on MHDETs.

It requires a detailed understanding of the dynamics within the sector, the key barriers to change, and the kinds of tools that have proven effective against such barriers. The barriers can be technological, they can grow out of archaic practices or regulations, or they can be socio-psychological. There’s no way to understand them and the opportunities for overcoming them until the stakeholders are heard, the data is crunched, and the analysis is done. It’s a hands-on, labor-intensive affair, especially if done well.

And because it involves so much effort from so many parties, it’s inevitably messy to implement, full of compromises and half-measures, rarely optimized to an economist’s satisfaction.

But throughout American history, industrial policy has produced wonders, from transistors and computers to pharmaceuticals, renewable energy, and, uh, fracking. If the US can muster the will, it can engineer a rapid transition from diesel trucks and buses to electric. It has done much bigger things than that.

The clean-energy transition will be accomplished not by any one policy, but sector by sector, fighting for every inch. Electrifying trucks and buses is worth the fight.